Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg\~120 mg in patients with mild to moderate essential hypertension.

Conditions

• Hypertension

Interventions

DRUG

Fimasartan

Fimasartan 60 \~ 120mg/po take one tablets once a day

DRUG

Losartan (Control)

Losartan 50 mg \~ 100 mg/po, take one tablets once a day

Sponsors & Collaborators

• Seoul National University Hospital

  collaborator OTHER

• The Catholic University of Korea

  collaborator OTHER

• Kangbuk Samsung Hospital

  collaborator OTHER

• Konkuk University Medical Center

  collaborator OTHER

• Konyang University Hospital

  collaborator OTHER

• Keimyung University

  collaborator OTHER

• Korea University

  collaborator OTHER

• Korea University Guro Hospital

  collaborator OTHER

• Dongguk University International Hospital

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Asan Medical Center

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Ajou University

  collaborator OTHER

• Wonju Severance Christian Hospital

  collaborator OTHER

• Yeungnam University Hospital

  collaborator OTHER

• Yonsei University

  collaborator OTHER

• Inha University Hospital

  collaborator OTHER

• Chonbuk National University Hospital

  collaborator OTHER

• Cheil General Hospital and Women's Healthcare Center

  collaborator OTHER

• Chungnam National University

  collaborator OTHER

• Chungbuk National University Hospital

  collaborator OTHER

• Hanyang University

  collaborator OTHER

• Boryung Pharmaceutical Co., Ltd

  lead INDUSTRY

Principal Investigators

• Byung-Hee Oh, MD · Seoul National University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-12-31

Primary Completion

2009-07-31

Completion

2009-09-30